BlackRock
PCVX icon

BlackRock’s Vaxcyte PCVX Stock Holding History

BlackRock’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702M Buy
12,068,129
+1,096,313
+10% +$59.5M 0.01% 963
2026
Q1 		$638M Buy
10,971,816
+725,438
+7% +$39.4M 0.01% 939
2025
Q4 		$473M Buy
10,246,378
+290,400
+3% +$13M 0.01% 1141
2025
Q3 		$359M Sell
9,955,978
-686,265
-6% -$22.7M 0.01% 1298
2025
Q2 		$346M Buy
10,642,243
+62,766
+0.6% +$2.06M 0.01% 1270
2025
Q1 		$399M Sell
10,579,477
-526,592
-5% -$42.1M 0.01% 1175
2024
Q4 		$909M Buy
11,106,069
+439,632
+4% +$43.7M 0.02% 699
2024
Q3 		$1.22B Buy
10,666,437
+726,591
+7% +$65.5M 0.03% 546
2024
Q2 		$751M Buy
9,939,846
+426,839
+4% +$29.1M 0.02% 744
2024
Q1 		$650M Buy
9,513,007
+937,160
+11% +$64.9M 0.02% 847
2023
Q4 		$539M Buy
8,575,847
+1,154,596
+16% +$60M 0.01% 950
2023
Q3 		$378M Buy
7,421,251
+356,163
+5% +$17.6M 0.01% 1093
2023
Q2 		$353M Buy
7,065,088
+1,983,223
+39% +$94M 0.01% 1170
2023
Q1 		$190M Sell
5,081,865
-23,505
-0.5% -$997K 0.01% 1574
2022
Q4 		$245M Buy
5,105,370
+1,613,049
+46% +$63.3M 0.01% 1379
2022
Q3 		$83.8M Buy
3,492,321
+220,691
+7% +$5.59M ﹤0.01% 2085
2022
Q2 		$71.2M Buy
3,271,630
+385,608
+13% +$8.92M ﹤0.01% 2251
2022
Q1 		$69.7M Buy
2,886,022
+108,975
+4% +$2.38M ﹤0.01% 2367
2021
Q4 		$66.1M Buy
2,777,047
+252,402
+10% +$5.87M ﹤0.01% 2473
2021
Q3 		$64.1M Buy
2,524,645
+178,028
+8% +$4.32M ﹤0.01% 2502
2021
Q2 		$52.8M Buy
2,346,617
+157,889
+7% +$3.23M ﹤0.01% 2663
2021
Q1 		$43.2M Buy
2,188,728
+495,700
+29% +$12.5M ﹤0.01% 2712
2020
Q4 		$45M Buy
1,693,028
+688,500
+69% +$25.6M ﹤0.01% 2541
2020
Q3 		$49.6M Buy
1,004,528
+924,716
+1,159% +$36.8M ﹤0.01% 2308
2020
Q2 		$2.52M Buy
+79,812
New +$2.57M ﹤0.01% 3764

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's PCVX Position: Q2 2026 in Review

BlackRock increased its Vaxcyte (PCVX) stake by 10% in Q2 2026, buying an estimated $59.5M and bringing the position to 12,068,129 shares worth $702M. The position accounts for 0.01% of the portfolio, ranked #963.

BlackRock first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.22B in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • BlackRock held 12,068,129 shares of Vaxcyte worth $702M as of Q2 2026.
  • BlackRock bought 1,096,313 Vaxcyte shares in Q2 2026, an estimated $59.5M.
  • Vaxcyte made up 0.01% of BlackRock's portfolio in Q2 2026, its #963 holding.
  • BlackRock first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • BlackRock's Vaxcyte position peaked at $1.22B in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.